Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $4.4 million.

  • Monte Rosa Therapeutics' Share-based Compensation rose 191.5% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 729.8%. This contributed to the annual value of $18.1 million for FY2024, which is 874.08% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Share-based Compensation stood at $4.4 million for Q3 2025, which was up 191.5% from $4.9 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Share-based Compensation's 5-year high stood at $5.3 million during Q1 2025, with a 5-year trough of $4.0 million in Q1 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Share-based Compensation value was $4.5 million (recorded in 2023), while the average stood at $4.5 million.
  • Over the last 5 years, Monte Rosa Therapeutics' Share-based Compensation had its largest YoY gain of 2262.2% in 2024, and its largest YoY loss of 416.29% in 2024.
  • Over the past 3 years, Monte Rosa Therapeutics' Share-based Compensation (Quarter) stood at $4.1 million in 2023, then increased by 9.7% to $4.5 million in 2024, then fell by 2.35% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.9 million for Q2 2025, and $5.3 million during Q1 2025.